Study shows possibilities for curing patients with early-stage Hodgkin's lymphoma of their cancer

NewsGuard 100/100 Score

Doctors in Germany have determined that patients suffering from early-stage Hodgkin's lymphoma can receive a reduced dose of involved field radiation therapy, combined with chemotherapy, and still retain a high survival rate, according to a study presented October 17, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.

If caught early, Hodgkin's lymphoma can usually be cured and most patients are living many years after their diagnosis. However, they often must live with side effects caused by the treatment. In this study, doctors wanted to see if they could reduce the amount of radiation given to patients in order to cut down on side effects and still cure them of their cancer.

Between May 1998 and May 2002, researchers studied 1,131 patients to see whether giving patients chemotherapy and reducing the amount of radiation (from 30 Gy to 20 Gy) would cure their cancer. The results showed that more than 98 percent of patients receiving the reduced treatment experienced complete remission from their disease. Only 2.5 percent of the patients relapsed during the study's two years of observation and 13 patients died from the disease during the course of the study.

"Although this was an interim study, the results are very encouraging that we can cure patients with early-stage Hodgkin's lymphoma of their cancer while reducing the amount of radiation we give them, thus allowing them to have a higher quality of life after treatment," said Hans Theodor Eich, M.D., lead author of the study and a radiation oncologist at the University of Cologne in Cologne, Germany.

http://www.astro.org/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer